{
    "root": "376e8626-79d8-4102-903d-104160f440b0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20250314",
    "ingredients": [
        {
            "name": "Diclofenac Sodium",
            "code": "QTG126297Q"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration and Perforation\n                     ).\n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                     \n                        •For relief of the signs and symptoms of osteoarthritis\n                     \n                        •For relief of the signs and symptoms of rheumatoid arthritis\n                     \n                        •For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ).\n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day or four times a day, or 75 mg twice a day).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25 mg dose at bedtime if necessary.\n                  Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions": "HOW SUPPLIED\n                      Diclofenac sodium delayed-release tablets, USP, for oral administration, are available as:\n                  \n                     75 mg: round, light brown, enteric-coated tablets\n                                  P        75\n                     imprinted on one side in black ink and plain on the reverse side are supplied as:\n                  \n                     Bottles of 30.........................................NDC 68788-8193-3\n                  Bottles of 60.........................................NDC 68788-8193-6\n                  Bottles of 90.........................................NDC 68788-8193-9\n                  Bottles of 100.........................................NDC 68788-8193-1\n                  Bottles of 120.........................................NDC 68788-8193-8\n                  Store at 20° to 25°C (68° to 77°F) (see USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container.\n                  \n                     Manufactured by:Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India.\n                  \n                     Distributed by:\n                  \n                  \n                  Rising Pharma Holdings, Inc.\n                  East Brunswick, NJ 08816\n                   1-800-521-5340\n                      139661\n                  Jul. 2024\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients.\n                  \n                     \n                        •Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see \n                           WARNINGS: Anaphylactic Reactions\n                        , \n                           Serious Skin Reactions\n                        ).\n                     \n                        •History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see \n                           WARNINGS: Anaphylactic Reaction\n                        , \n                           Exacerbation of Asthma Related to Aspirin Sensitivity\n                        ).\n                     \n                        •In the setting of coronary artery bypass graft (CABG) surgery (see \n                           WARNINGS: Cardiovascular Thrombotic Events)."
}